Multiple myeloma: open trials in United Kingdom

50 open trials have a site in United Kingdom. Registry data; only the trial team decides who can take part.

NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Aberdeen Royal Infirmary, Aberdeen · University Hospitals Birmingham NHS Trust, Center for Clinical, Birmingham · Ninewells Hospital and Medical School, Dundee · University of Manchester, Manchester Royal Infirmary, Manchester · Norfolk and Norwich University Hospital National Health Service (NHS) Foundation Trust, Norwich · University Hospitals Plymouth National Health Service (NHS) Foundation Trust - Hematology, Plymouth · The Royal Marsden National Health Service (NHS) Foundation Trust; Royal Marsden Hospital, Sutton · Royal Cornwall Hospital National Health Service (NHS) Foundation Trust, Truro
Registry updated 2026-11-04
NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
University Hospitals Leicester, Leicester · Saint Bartholomew's Hospital, London · Hammersmith Hospital, Imperial College Healthcare NHS Trust, London · Norfolk and Norwich University Hospital, Norwich · The Royal Marsden NHS Foundation Trust, Sutton · Royal Cornwall Hospital, Truro
Registry updated 2026-11-04
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
University Hospitals Birmingham NHS Foundation Trust, Birmingham · Blackpool Victoria Hospital, Blackpool · Bristol NHS Foundation Trust, Bristol · Addenbrooke's Hospital, Cambridge · Kent and Canterbury Hospital, Canterbury · Western General Hospital, Edinburgh · Imperial College Healthcare, London · University College London Hospitals, London · New Cross Hospital, Wolverhampton
Registry updated 2026-11-03
NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
University College Hospital, London · Royal Marsden Hospital, Sutton
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Kent and Canterbury Hospital, Canterbury · Cardiff and Vale UHB - University Hospital of Wales, Cardiff · Ninewells Hospital & Medical School, Dundee · University College London Hospitals, London · Nottingham City Hospital, Nottingham · Queen Alexandra Hospital, Portsmouth · Royal Marsden Hospital, Sutton
Registry updated 2026-11-03
NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
University Hospitals Birmingham NHS Foundation Trust, Birmingham · Blackpool Victoria Hospital, Blackpool · Bristol NHS Foundation Trust, Bristol · Addenbrooke's Hospital, Cambridge · Kent and Canterbury Hospital, Canterbury · Colchester Hospital University NHS, Colchester · Western General Hospital, Edinburgh · New Cross Hospital, Heath Town · University College Hospital, London
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Lanarkshire NHS Trust - Monklands Hospital, Airdrie · Barnet Hospital, Barnet · Addenbrooke's Hospital, Cambridge · Leicester Royal Infirmary, Leicester · Hammersmith Hospital, London · King's College Hospital, London · Freeman Hospital, Newcastle upon Tyne · Royal Stoke University Hospital, Stoke-on-Trent · The Royal Cornwall Hospital, Truro
Registry updated 2026-10-30
NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · AstraZeneca
Leeds · Manchester · Plymouth
Registry updated 2026-10-30
NCT07284758
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · C4 Therapeutics, Inc.
NHS Lothian - Western General Hospital- Edinburgh Cancer Centre, Edinburgh · The Leeds Teaching Hospitals NHS Trust - St James's University Hospital, Leeds · Imperial College Healthcare NHS Foundation Trust, Hammersmith Hospital, London · The King's College Hospital NHS Foundation Trust, London · The Christie NHS Foundation Trust, Manchester · Newcastle University Hospitals NHS Foundation Trust, Newcastle upon Tyne · GenesisCare, Beaumont House, Oxford · The Royal Marsden NHS Foundation Trust, Sutton · GenesisCare, Windsor, Windsor
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Addenbrooke's Hospital, Cambridge · University College London Hospital, London · The Christie NHS Foundation Trust, Manchester · Freeman Hospital, Newcastle upon Tyne · Churchill Hospital, Oxford · Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Queen Elizabeth Hospital Birmingham, Birmingham · University Hospital of Wales, Cardiff · Western General Hospital, Edinburgh · The Beatson West of Scotland Cancer Centre, Glasgow · Leicester Royal Infirmary, Leicester · Guy's & St Thomas' NHS Foundation Trust, London · Churchill Hospital, Oxford · Royal Berkshire Hospital, Reading · Royal Stoke University Hospital, Stoke-on-Trent
Registry updated 2026-10-27
NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie
The Christie NHS Foundation Trust - Christie Hospital /ID# 276276, Manchester · Oxford University Hospital NHS Trust /ID# 276958, Oxford
Registry updated 2026-10-27
NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals
Royal Marsden Hospital, Sutton
Registry updated 2026-10-26
NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Trial Treatment · Phase 1/2 · BeOne Medicines
Oxford University Hospitals Nhs Trust Churchill Hospital, Headington · University College Hospital, London · Royal Marsden Nhs Foundation Royal Marsden Hospital, Sutton
Registry updated 2026-10-26
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Cambridge · London
Registry updated 2026-10-21
NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Genentech, Inc.
University College London Hospitals NHS Foundation Trust, London · Royal Marsden Hospital, Sutton
Registry updated 2026-10-20
NCT06762769
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Trial Treatment · Phase 2 · University College, London
Aberdeen Royal Infirmary, Aberdeen · University of Birmingham Hospital, Birmingham · Bristol NHS Foundation Trust, Bristol · Cardiff and Vale University Health Board, Cardiff · University Hospitals of Derby and Burton, Derby · St James University Hospital, Leeds · King's College Hospital NHS Foundation Trust, London · University College London Hospital, London · St Georges Hospital, London · Barts Health Trust, London · Nottingham City Hospital, Nottingham · George Eliot Hospital, Nuneaton · Churchill Hospital, Oxford · Glan Clwyd Hospital, Wales
Registry updated 2026-10-20
NCT06892522
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Trial Treatment · Phase 1/2 · AbbVie
University Hospitals Birmingham NHS Foundation Trust /ID# 274620, Birmingham · University Hospital of Wales /ID# 273446, Cardiff · Hammersmith Hospital /ID# 274615, London
Registry updated 2026-10-19
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
Leicester Royal Infirmary, Leicester · Hammersmith Hospital, London · St. Bartholomew's Hospital, London
Registry updated 2026-10-14
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
Cardiff & Vale University Health Board, Cardiff · Colchester General Hospital, Colcester · Royal Devon and Exeter Hospital, Exeter · Gloucestershire Royal Hospital, Gloucester · Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes · County Hospital (Stafford Hospital), Stafford
Registry updated 2026-10-13
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
University College London Hospitals NHS Foundation Trust, London · Oxford Churchill Hospital, Oxford · The Royal Wolverhampton Hospitals NHS Trust, Wolverhampton
Registry updated 2026-10-13
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Hammersmith Hospital - Imperial College NHS Healthcare Trust, London · University College London (UCL), London · The Royal Marsden Hospital, Sutton
Registry updated 2026-10-07
NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Queen Elizabeth Hospital Birmingham, Birmingham · Addenbrooke's Hospital, Cambridge · Western General Hospital, Edinburgh · Hammersmith Hospital, London · Barts Health NHS Trust, London · Guy's & St Thomas' NHS Foundation Trust, London · Royal Marsden Hospital, London · The Christie NHS Foundation Trust, Manchester
Registry updated 2026-10-07
NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Trial Treatment · Phase 3 · AstraZeneca
Birmingham · Bristol · Glasgow, Scotland · London
Registry updated 2026-09-29
NCT06500884
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Belfast City Hospital, Belfast · Colchester Hospital University NHS, Colchester · Eastbourne District General Hospital, Eastbourne · The Clatterbridge Cancer Centre, Liverpool · Hammersmith Hospital, London · University College London Hospitals, London · The Christie NHS Foundation Trust - Christie Hospital, Manchester · Newcastle Freeman Hospital, Newcastle upon Tyne
Registry updated 2026-09-25

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error